Moderna initiates phase III study of RSV vaccine

The US-based biotech company now enters the last phase with its vaccine candidate against RSV.
Photo: Dado Ruvic/REUTERS / X02714
Photo: Dado Ruvic/REUTERS / X02714
by VICTOR EMIL KRISTENSEN, translated by daniel pedersen

US-based Moderna is entering the final sprint in the race to have the first vaccine against respiratory syncytial virus (RSV), as reported by Danish business daily Børsen in connection with a company press release, which declared that two successful phase II trials have opened the pathway to a phase III study.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading